Gene One Life Science, VGXI Ordered to Pay USD 80.42 Million in Inovio Lawsuit

Bitget2026/10/21 10:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gene One Life Science and subsidiary VGXI face a USD 80.42 million default judgment in favor of Inovio Pharmaceuticals.
Pennsylvania’s Montgomery County court issued the October 19, 2026 ruling over alleged breaches of a DNA plasmid supply agreement and technology-transfer obligations.
The award comprises USD 61.75 million in damages and USD 18.67 million in attorneys’ fees and expenses.
The judgment totals KRW 106.46 billion, equivalent to 260.3% of the company’s equity.
The company and subsidiary plan to seek to vacate the judgment and pursue an appeal, citing procedural and substantive objections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800687), on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gene One Life Science, VGXI Ordered to Pay USD 80.42 Million in Inovio Lawsuit

You may also like

Crypto prices